MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic PLC (MDT) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive catalysts such as hedge fund buying and the growth potential in the cardiovascular devices market, the company's recent financial performance shows declining net income, EPS, and gross margin. Additionally, analyst ratings and price target revisions indicate cautious sentiment, with several firms lowering their targets. The technical indicators and options data do not suggest a strong bullish trend, and there are no significant trading signals from Intellectia Proprietary Trading Signals. Therefore, it is best to hold off on buying MDT at this time.
The MACD is positive at 0.35 and contracting, suggesting mild bullish momentum. RSI is neutral at 32.854, and moving averages are converging, indicating no clear trend. Key support is at 85.696, and resistance is at 88.469. The stock is trading near support levels, but there is no strong technical signal for a breakout.
Hedge funds are significantly increasing their buying activity (167.88% increase last quarter).
The U.S. cardiovascular devices market is expected to grow significantly, benefiting Medtronic's core business.
Analysts acknowledge potential revenue accelerants in upcoming quarters.
Declining financial performance in Q3 2026, with net income down 11.67% YoY and EPS down 11.88%.
Analysts have broadly reduced price targets, reflecting cautious sentiment.
No recent congress trading data or significant insider activity to support bullish sentiment.
In Q3 2026, revenue increased by 8.74% YoY to $9.017 billion, but net income dropped by 11.67% YoY to $1.143 billion. EPS declined by 11.88% YoY to $0.89, and gross margin fell to 59.93%, down 2.58% YoY. This mixed performance reflects challenges in profitability despite revenue growth.
Analyst sentiment is mixed to cautious. Several firms have lowered their price targets recently, with targets ranging from $91 to $120. Ratings include Hold, Outperform, and Buy, but there is no consensus on strong upside potential in the near term.
